Labopharm, a Canadian pharmaceutical firm, has appointed Sylvain Guénette as chief financial officer (CFO). Guénette, a chartered accountant, joined Labopharm as controller in 2002 and was most recently vice president and corporate controller. Prior to joining Labopharm, Guénette was corporate controller at Les Systèmes Proxima Ltée and director of finance and operations at the Montreal office of Nurun. Guenette has also held various finance and accounting positions within the Quebecor Group.
On 14 March, 2011, Mark D’Souza, Lambopharm’s then CFO, was named as new president and chief executive officer (CEO). D’Souza replaced James Howard-Tripp, who resigned from Labopharm’s board of directors.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.